Safety of Rabeprazole in Patients Under Multiple Treatments
Status:
Terminated
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of rabeprazole 20mg/day in polymedicated
patients and to examine the necessity of adjusted dosage in both therapies (rabeprazole and
concomitant drug). Proton pump inhibitors (PPI) act in the final step of the gastric
secretion. PPI's block ATP-ase H+/K+ in gastric parietals cells. It has been described that
inhibition of acid secretion has produced the recovery of the gastroesophageal pathology in a
high percentage of the patients resistant to conventional drugs. In this context, the
objective of the study is to evaluate the safety of rabeprazole as a concomitant treatment
and examine the clinical practice the interaction with drugs whose absorption has gastric pH
dependence.